Methods and compositions for treating fibrotic diseases

Abstract

The invention provides methods and compositions for the prevention or treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis. In particular, the invention provides methods for the prevention or treatment of fibrotic diseases and pre-fibrotic diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention or treatment fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis.

1 . A method for treating or preventing fibrotic disease in an individual comprising administering to the individual an effective amount of an antibody that binds to human Siglec-8; wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and wherein the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:66. 
     
     
         2 . The method of  claim 1 , wherein the fibrotic disease is selected from the group consisting of: pulmonary fibrosis, hepatic fibrosis, renal fibrosis, cardiac fibrosis, spleen fibrosis, ocular fibrosis, mechanical-induced fibrosis, implant-induced fibrosis, radiation-induced fibrosis, drug-induced fibrosis, viral-induced fibrosis, cystic fibrosis, cancer-associated fibrosis, atherosclerosis, bone marrow fibrosis, scleroderma, mediastinal fibrosis, retroperitoneal cavity fibrosis, and Dupuytren's contracture. 
     
     
         3 . The method of  claim 2 , wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis. 
     
     
         4 . The method of  claim 2 , wherein the pulmonary fibrosis is associated with chronic obstructive pulmonary disease. 
     
     
         5 . (canceled) 
     
     
         6 . The method of  claim 2 , wherein the mechanical induced fibrosis is ventilator-induced pulmonary fibrosis. 
     
     
         7 . The method of  claim 2 , wherein the drug-induced fibrosis is bleomycin-induced pulmonary fibrosis. 
     
     
         8 . (canceled) 
     
     
         9 . The method of  claim 2 , wherein the scleroderma is systemic sclerosis. 
     
     
         10 . The method of  claim 1 , wherein one or more symptom in the individual with the fibrotic disease is reduced relative to baseline after administration of the antibody that binds to human Siglec-8. 
     
     
         11 . The method of  claim 1 , wherein one or more pulmonary function in the individual with pulmonary fibrosis is increased by at least 5% relative to baseline after administration of the antibody that binds to human Siglec-8. 
     
     
         12 . The method of  claim 11 , wherein the one or more pulmonary function is selected from the group consisting of: vital capacity (VC), residual volume (V), forced expiratory volume (FEV 1 ), forced vital capacity (FVC), forced expiratory flow (FEF), peak expiratory flow rate (PEFR), inspiratory reserve volume (IRV), functional residual capacity (FRC), inspirator capacity (IC), total lung capacity (TLC), expiratory reserve volume (ERV), tidal volume (TV) and maximum voluntary ventilation (MVV). 
     
     
         13 . The method of  claim 1 , wherein one or more pathologic parameter in the individual with fibrotic disease is reduced by at least 5% relative to baseline after administration of the antibody that binds to human Siglec-8. 
     
     
         14 . The method of  claim 13 , wherein the one or more pathologic parameter is selected from the group consisting of: neutrophil influx, number of mast cells, cytokine release, collagen accumulation, fibroblast or myofibroblast infiltration and fibroblastic foci formation. 
     
     
         15 - 16 . (canceled) 
     
     
         17 . The method of  claim 1 , wherein mast cell activation is reduced in the individual relative to baseline after administration of the antibody that binds to human Siglec-8. 
     
     
         18 . The method of  claim 1 , wherein the antibody is a monoclonal antibody. 
     
     
         19 - 21 . (canceled) 
     
     
         22 . The method of  claim 1 , wherein at least one or two of the heavy chains of the antibody is non-fucosylated. 
     
     
         23 . The method of  claim 1 , wherein the antibody is a humanized antibody or a chimeric antibody. 
     
     
         24 - 27 . (canceled) 
     
     
         28 . The method of  claim 1 , wherein the antibody comprises a heavy chain Fc region comprising a human IgG Fc region. 
     
     
         29 . The method of  claim 28 , wherein the human IgG Fc region comprises a human IgG1 or a human IgG4. 
     
     
         30 . The method of  claim 29 , wherein the human IgG4 comprises the amino acid substitution S228P, and wherein the amino acid residues are numbered according to the EU index as in Kabat. 
     
     
         31 - 41 . (canceled) 
     
     
         42 . The method of  claim 1 , wherein the individual is a human. 
     
     
         43 - 104 . (canceled)